Chemours (NYSE:CC) Trading Down 5.8% – Here’s What Happened

Shares of The Chemours Company (NYSE:CC) were down 5.8% during mid-day trading on Thursday . The company traded as low as $20.42 and last traded at $20.9750. Approximately 929,412 shares traded hands during trading, a decline of 72% from the average daily volume of 3,317,872 shares. The stock had previously closed at $22.27.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Zacks Research sharply lowered its Q2 2026 EPS estimate for Chemours to $0.33 from $0.60, signaling weaker near-term profitability expectations. Chemours analyst estimate cut
• Negative Sentiment: The firm also cut FY2026 EPS estimates to $0.90 from $1.06, reinforcing concerns that earnings momentum may be softer than previously expected. Chemours FY2026 estimate cut
• Negative Sentiment: Several other near-term outlooks were trimmed, including Q3 2026 and Q1/Q2 2027, suggesting analysts see a weaker earnings path over the next several quarters. Chemours multiple estimate revisions
• Neutral Sentiment: Zacks Research maintained a Hold rating on Chemours, indicating a cautious but not outright bearish stance. Chemours Hold rating
• Positive Sentiment: Not all estimates moved lower: Zacks raised its Q3 2027 and Q4 2027 EPS forecasts slightly, and FY2028 remains above FY2027, suggesting longer-term earnings improvement is still possible. Chemours longer-term estimates

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CC shares. JPMorgan Chase & Co. boosted their price target on shares of Chemours from $13.00 to $17.00 and gave the company a “neutral” rating in a report on Monday, February 23rd. BMO Capital Markets lowered their price target on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, February 23rd. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a report on Friday, April 24th. Jefferies Financial Group reissued a “hold” rating and issued a $17.00 price target on shares of Chemours in a report on Monday, February 23rd. Finally, The Goldman Sachs Group boosted their price target on shares of Chemours from $14.00 to $18.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Chemours has a consensus rating of “Hold” and an average target price of $23.09.

Chemours Price Performance

The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82. The company’s 50 day moving average price is $22.29 and its 200 day moving average price is $17.25. The company has a market cap of $3.26 billion, a price-to-earnings ratio of -8.21 and a beta of 1.47.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The company had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. On average, equities research analysts predict that The Chemours Company will post 1.27 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th will be paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Friday, May 15th. Chemours’s payout ratio is currently -13.26%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CC. Baird Financial Group Inc. acquired a new position in Chemours during the 1st quarter worth about $148,000. Royal Bank of Canada lifted its position in Chemours by 6.8% during the 1st quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock worth $7,926,000 after buying an additional 37,382 shares in the last quarter. AQR Capital Management LLC acquired a new position in Chemours during the 1st quarter worth about $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Chemours by 149.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock worth $593,000 after buying an additional 25,899 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Chemours during the 1st quarter worth about $403,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.